Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jan, 2015 | Pages:
161 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Anthrax - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Anthrax - Pipeline Review, H1 2015', provides an overview of the Anthrax's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Anthrax, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anthrax and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Anthrax - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Anthrax and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Anthrax products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Anthrax pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Anthrax - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Anthrax pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Anthrax Overview 9 Therapeutics Development 10 Pipeline Products for Anthrax - Overview 10 Pipeline Products for Anthrax - Comparative Analysis 11 Anthrax - Therapeutics under Development by Companies 12 Anthrax - Therapeutics under Investigation by Universities/Institutes 16 Anthrax - Pipeline Products Glance 17 Late Stage Products 17 Clinical Stage Products 18 Early Stage Products 19 Anthrax - Products under Development by Companies 20 Anthrax - Products under Investigation by Universities/Institutes 23 Anthrax - Companies Involved in Therapeutics Development 24 Aduro BioTech, Inc. 24 Aradigm Corporation 25 Bavarian Nordic A/S 26 Bristol-Myers Squibb Company 27 ContraFect Corporation 28 Dynavax Technologies Corporation 29 Elusys Therapeutics, Inc. 30 Emergent BioSolutions Inc. 31 Evolva SA 32 Green Cross Corporation 33 Grifols, S.A. 34 Hawaii Biotech, Inc. 35 iBio, Inc. 36 Immunovaccine, Inc. 37 Innovative Biologics, Inc. 38 Microbiotix, Inc. 39 NanoBio Corporation 40 Navigen Pharmaceuticals, Inc. 41 Oragenics, Inc. 42 PaxVax 43 Pfenex Inc. 44 Planet Biotechnology Inc. 45 Protein Potential, LLC 46 ProThera Biologics, LLC. 47 PsiOxus Therapeutics, Ltd. 48 Revivicor, Inc. 49 SelectX Pharmaceuticals, Inc. 50 Soligenix, Inc. 51 Summit Corporation plc 52 Syntiron LLC 53 Tetraphase Pharmaceuticals Inc. 54 The Medicines Company 55 Vaxin, Inc. 56 Anthrax - Therapeutics Assessment 57 Assessment by Monotherapy Products 57 Assessment by Combination Products 58 Assessment by Target 59 Assessment by Mechanism of Action 61 Assessment by Route of Administration 63 Assessment by Molecule Type 65 Drug Profiles 67 anthrax + plague vaccine - Drug Profile 67 anthrax vaccine - Drug Profile 68 anthrax vaccine - Drug Profile 70 anthrax vaccine - Drug Profile 71 anthrax vaccine - Drug Profile 72 anthrax vaccine - Drug Profile 73 anthrax vaccine - Drug Profile 74 anthrax vaccine - Drug Profile 75 anthrax vaccine - Drug Profile 76 anthrax vaccine - Drug Profile 78 anthrax vaccine - Drug Profile 80 anthrax vaccine next generation - Drug Profile 81 ARD-3100 - Drug Profile 82 AV-7909 - Drug Profile 84 CF-307 - Drug Profile 85 CF-308 - Drug Profile 86 ciprofloxacin hydrochloride - Drug Profile 87 DPX-Anthrax - Drug Profile 88 DV-230 - Drug Profile 89 EV-021 - Drug Profile 90 GC-1109 - Drug Profile 91 GREANX - Drug Profile 92 Human Antibody Based Vaccines - Drug Profile 93 KKL-35 - Drug Profile 95 MDX-1303 - Drug Profile 96 Monoclonal Antibody for Respiratory Anthrax - Drug Profile 98 Monoclonal Antibody to Inhibit Anthrax Protective Antigen for Anthrax - Drug Profile 99 MU-1140 - Drug Profile 100 MVA-BN Anthrax - Drug Profile 102 NP-015 - Drug Profile 103 obiltoxaximab - Drug Profile 104 oritavancin diphosphate - Drug Profile 106 PBI-220 - Drug Profile 109 PreviThrax - Drug Profile 111 Proteins to Inhibit Furin for Anthrax Intoxication and Sepsis - Drug Profile 113 Px-563L - Drug Profile 114 RiVax + VeloThrax - Drug Profile 115 Second Generation Px-563L - Drug Profile 116 SGX-204 - Drug Profile 117 Slit2N - Drug Profile 118 Small Molecule to Inhibit Anthrax Toxin for Anthrax - Drug Profile 120 Small Molecules for Bacterial Infections - Drug Profile 121 Small Molecules to Inhibit Anthrax Lethal Factor Toxin for Anthrax - Drug Profile 122 Small Molecules to Inhibit Lethal Factor for Anthrax - Drug Profile 123 Small Molecules to Inhibit Lethal Factor for Anthrax and Cystic Fibrosis - Drug Profile 125 Small Molecules to Inhibit MMP - Drug Profile 126 SMT-15000 - Drug Profile 127 TP-271 - Drug Profile 128 Anthrax - Recent Pipeline Updates 130 Anthrax - Dormant Projects 143 Anthrax - Discontinued Products 146 Anthrax - Product Development Milestones 147 Featured News & Press Releases 147 Appendix 157 Methodology 157 Coverage 157 Secondary Research 157 Primary Research 157 Expert Panel Validation 157 Contact Us 157 Disclaimer 158
List of Tables Number of Products under Development for Anthrax, H1 2015 13 Number of Products under Development for Anthrax - Comparative Analysis, H1 2015 14 Number of Products under Development by Companies, H1 2015 16 Number of Products under Development by Companies, H1 2015 (Contd..1) 17 Number of Products under Development by Companies, H1 2015 (Contd..2) 18 Number of Products under Investigation by Universities/Institutes, H1 2015 19 Comparative Analysis by Late Stage Development, H1 2015 20 Comparative Analysis by Clinical Stage Development, H1 2015 21 Comparative Analysis by Early Stage Development, H1 2015 22 Products under Development by Companies, H1 2015 23 Products under Development by Companies, H1 2015 (Contd..1) 24 Products under Development by Companies, H1 2015 (Contd..2) 25 Products under Investigation by Universities/Institutes, H1 2015 26 Anthrax - Pipeline by Aduro BioTech, Inc., H1 2015 27 Anthrax - Pipeline by Aradigm Corporation, H1 2015 28 Anthrax - Pipeline by Bavarian Nordic A/S, H1 2015 29 Anthrax - Pipeline by Bristol-Myers Squibb Company, H1 2015 30 Anthrax - Pipeline by ContraFect Corporation, H1 2015 31 Anthrax - Pipeline by Dynavax Technologies Corporation, H1 2015 32 Anthrax - Pipeline by Elusys Therapeutics, Inc., H1 2015 33 Anthrax - Pipeline by Emergent BioSolutions Inc., H1 2015 34 Anthrax - Pipeline by Evolva SA, H1 2015 35 Anthrax - Pipeline by Green Cross Corporation, H1 2015 36 Anthrax - Pipeline by Grifols, S.A., H1 2015 37 Anthrax - Pipeline by Hawaii Biotech, Inc., H1 2015 38 Anthrax - Pipeline by iBio, Inc., H1 2015 39 Anthrax - Pipeline by Immunovaccine, Inc., H1 2015 40 Anthrax - Pipeline by Innovative Biologics, Inc., H1 2015 41 Anthrax - Pipeline by Microbiotix, Inc., H1 2015 42 Anthrax - Pipeline by NanoBio Corporation, H1 2015 43 Anthrax - Pipeline by Navigen Pharmaceuticals, Inc., H1 2015 44 Anthrax - Pipeline by Oragenics, Inc., H1 2015 45 Anthrax - Pipeline by PaxVax, H1 2015 46 Anthrax - Pipeline by Pfenex Inc., H1 2015 47 Anthrax - Pipeline by Planet Biotechnology Inc., H1 2015 48 Anthrax - Pipeline by Protein Potential, LLC, H1 2015 49 Anthrax - Pipeline by ProThera Biologics, LLC., H1 2015 50 Anthrax - Pipeline by PsiOxus Therapeutics, Ltd., H1 2015 51 Anthrax - Pipeline by Revivicor, Inc., H1 2015 52 Anthrax - Pipeline by SelectX Pharmaceuticals, Inc., H1 2015 53 Anthrax - Pipeline by Soligenix, Inc., H1 2015 54 Anthrax - Pipeline by Summit Corporation plc, H1 2015 55 Anthrax - Pipeline by Syntiron LLC, H1 2015 56 Anthrax - Pipeline by Tetraphase Pharmaceuticals Inc., H1 2015 57 Anthrax - Pipeline by The Medicines Company, H1 2015 58 Anthrax - Pipeline by Vaxin, Inc., H1 2015 59 Assessment by Monotherapy Products, H1 2015 60 Assessment by Combination Products, H1 2015 61 Number of Products by Stage and Target, H1 2015 63 Number of Products by Stage and Mechanism of Action, H1 2015 65 Number of Products by Stage and Route of Administration, H1 2015 67 Number of Products by Stage and Molecule Type, H1 2015 69 Anthrax Therapeutics - Recent Pipeline Updates, H1 2015 133 Anthrax - Dormant Projects, H1 2015 146 Anthrax - Dormant Projects (Contd..1), H1 2015 147 Anthrax - Dormant Projects (Contd..2), H1 2015 148 Anthrax - Discontinued Products, H1 2015 149
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
